Literature DB >> 8674889

Hyperinsulinemia and atherosclerosis.

R W Stout1.   

Abstract

For more than 25 years, there has been an expansion in the clinical and experimental evidence linking hyperinsulinemia with cardiovascular disease and atherosclerosis. Assessment of the evidence under the headings of the strength of the association, dose response, temporality, consistency, specificity, and plausibility supports the concept that hyperinsulinemia has a causal role in atherogenesis. Evidence that reducing insulin levels prevents atherosclerosis is lacking. The evidence available is strong enough to support preventive measures to lower insulin levels such as regular physical exercise and avoidance of obesity.

Entities:  

Mesh:

Year:  1996        PMID: 8674889     DOI: 10.2337/diab.45.3.s45

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  Rosiglitazone: trials, tribulations and termination.

Authors:  Andrew J Krentz
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

3.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

4.  The relationship of management modality in Saudi patients with type 2 diabetes to components of metabolic syndrome, γ glutamyl transferase and highly sensitive C-reactive protein.

Authors:  Suhad M Bahijri; Maimoona Ahmed; Khalid Al-Shali; Samia Bokhari; Amani Alhozali; Anwar Borai; Amani Gusti; Ghada Ajabnoor; Ahmed Alghamdi; Mohammed Asiri; Jaakko Tuomilehto
Journal:  Ther Adv Chronic Dis       Date:  2016-07-15       Impact factor: 5.091

5.  Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp.

Authors:  B Zethelius; H Lithell; C N Hales; C Berne
Journal:  Diabetologia       Date:  2005-04-01       Impact factor: 10.122

Review 6.  Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.

Authors:  A Evans; A J Krentz
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

7.  Aging and atherosclerosis in human and nonhuman primates.

Authors:  W T Cefalu; J D Wagner
Journal:  Age (Omaha)       Date:  1997-01

8.  RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells.

Authors:  Ling-Qing Yuan; Jia-Hua Zhu; Hua-Wen Wang; Qiu-Hua Liang; Hui Xie; Xian-Ping Wu; Hua Zhou; Rong-Rong Cui; Zhi-Feng Sheng; Hou-De Zhou; Xiao Zhu; Guan-Ying Liu; You-Shuo Liu; Er-Yuan Liao
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

Review 9.  Early insulin use in type 2 diabetes: what are the cons?

Authors:  Jean-Louis Chiasson
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

10.  Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.

Authors:  Daisuke Kitano; Masaaki Chiku; Yuxin Li; Yasuo Okumura; Daisuke Fukamachi; Tadateru Takayama; Takafumi Hiro; Satoshi Saito; Atsushi Hirayama
Journal:  Cardiovasc Diabetol       Date:  2013-06-19       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.